Sign In

Hung Trinh

Associate Director of Downstream Process Development at Genezen

Hung Trinh is a prominent figure in the biotechnology sector, currently serving as the Senior Director of Business Development at OBiO Tech. He has a substantial background in process development and manufacturing, particularly within the realm of biopharmaceuticals.

Professional Background

  • Current Role: Senior Director of Business Development at OBiO Tech.
  • Previous Positions:
    • Director of Process Development and Manufacturing Science and Technology at Vyriad.
    • Associate Director of Downstream Process Development at Genezen.

Trinh has extensive experience in vaccine development and has worked on various projects focusing on lentiviral vector production and CAR-T cell manufacturing. His expertise encompasses both pre-clinical and clinical studies, making him well-versed in the complexities of drug development processes.

Education and Expertise

Hung Trinh holds a Ph.D. specializing in Molecular Virology, with a strong focus on viral vectors, analytical methods, and bioassay development. His academic background supports his practical experience in the biotech industry, contributing to his effective leadership in business development roles.

Contributions to the Industry

Trinh is recognized for his insights into the contract development and manufacturing organization (CDMO) landscape, having shared valuable information regarding industry trends and challenges through platforms like LinkedIn. His contributions are particularly relevant as the industry faces shifts in demand from large pharmaceutical companies.

For more information about his professional journey, you can find him on LinkedIn under the username hung-trinh-47b3aa84.

Highlights

Sep 6 · linkedin

Allogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosis

Highlights •TyU19 is a genetically engineered, healthy donor-derived CD19-targeting CAR-T product •TyU19 caused B cell depletion in three patients with refractory autoimmune diseases •TyU19 alleviated severe skeletal muscle damage in a patient with refractory IMNM •TyU19 reversed extensive fibrotic damage to critical organs in two patients with dcSSc

Summary Allogeneic chimeric antigen receptor (CAR)-T cells hold great promise for expanding the accessibility of CAR-T therapy, whereas the risks of allograft rejection have hampered its application. Here, we genetically engineered healthy-donor-derived, CD19-targeting CAR-T cells using CRISPR-Cas9 to address the issue of immune rejection and treated one patient with refractory immune-mediated necrotizing myopathy and two patients with diffuse cutaneous systemic sclerosis with these cells. This study was registered at ClinicalTrials.gov (NCT05859997). The infused cells persisted for over 3 months, achieving complete B cell depletion within 2 weeks of treatment. During the 6-month follow-up, we observed deep remission without cytokine release syndrome or other serious adverse events in all three patients, primarily shown by the significant improvement in the clinical response index scores for the two diseases, respectively, and supported by the observations of reversal of inflammation and fibrosis. Our results demonstrate the high safety and promising immune modulatory effect of the off-the-shelf CAR-T cells in treating severe refractory autoimmune diseases.

https://lnkd.in/ePEXUVrb

Sep 2 · linkedin

Yale School of Medicine: Yale Study Highlights Unmet Needs for Patients With Melanoma Who Progress or Relapse After Immunotherapy Treatment

A retrospective cohort study by Yale Cancer Center researchers of nearly 200 patients with melanoma who died after receiving treatment with immunotherapy highlights a need to improve outcomes for patients after the treatment. The study of 183 patients with metastatic melanoma who died between 2009 and 2023 following immunotherapy treatment investigated sites of metastases at death in addition to settings and mechanisms of death. “Notably, the associations identified between the sites of metastases and causes of death may inform management for patients with end-stage melanoma,” the study said. Many factors concerning melanoma mortality are poorly understood, posing an obstacle to optimal care and the development of new treatment approaches. The study notes that despite the successes of immunotherapy in decreasing melanoma mortality, many patients continue to experience treatment resistance. The study, in describing factors associated with melanoma mortality, demonstrates the ongoing need for therapeutic advancements. Primary authors of the study, published in Pigment Cell & Melanoma Research, are Daniel Y. Lee, MD, internal medicine resident, and Madeline McNamara, Yale School of Medicine student; senior author is Jeffrey Ishizuka, MD, DPhil, assistant professor, medical oncology, and PI of the Ishizuka Lab at Yale Cancer Center. Melanoma is the deadliest skin cancer, claiming 57,000 lives annually worldwide. The advent of immune checkpoint inhibitors pushed the five-year overall survival among patients with metastatic melanoma from 5% to more than 50%, and novel immunotherapies for metastatic melanoma continue to be developed. But not everyone benefits from the treatment. The study found that 87.9% of patients in the cohort who died with metastatic melanoma did so from melanoma-specific causes, paralleling findings in other studies. Even among the patients in the cohort who died more than five years after the diagnosis of metastatic disease, most deaths (76.2%) were attributable to melanoma. “While the prognosis of patients with metastatic melanoma has dramatically improved, there remains an unmet need to improve outcomes for patients who progress or relapse after treatment with immunotherapy. Precise characterization of settings and mechanisms of death in this high-risk group may refine interventions and management for these patients,” Lee said.

https://lnkd.in/e9deegZa

Related Questions

What are Hung Trinh's main responsibilities at OBiO Tech?
How has Hung Trinh's career evolved over the years?
What specific projects has Hung Trinh worked on at Genezen?
What is Hung Trinh's educational background?
How does Hung Trinh contribute to the field of CAR-T cell manufacturing?
Hung Trinh
Hung Trinh, photo 1
Hung Trinh, photo 2
Add to my network

Location

Indianapolis, Indiana, United States